Aimmune Therapeutics

Sep 01, 2020

Nestle acquires peanut allergy treatment with USD 2 Billion Aimmune buyout Nestle has announced a definitive agreement to extend its acquisition of Aimmune Therapeutics. Nestle will pay an additional amount of USD 2 Billion to buy the remaining shares of Aimmune. With the acquisition, Nestle will gain Aimmune's ...

Feb 04, 2020

The US FDA has given its recommendation to the Aimmune Therapeutics’ drug, Palforzia, the first-ever treatment for Peanut Allergy. Palforzia is an oral immunotherapy, set to address the unmet needs in the Peanut market, reducing the incidence and severity of allergic reactions, including anaphylaxis, which may ...

Jan 06, 2020

Hen’s egg allergy is the second most common type of allergy after cow’s milk. In infants and young children, Egg poses as one of the most vital allergens degrading the quality of life.  As per estimates, as many as 2 per cents of children are allergic to eggs. However, around 70% of these children are fortunate ...